LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
Brown LC, Tucker MD, Sedhom R, Schwartz EB, Zhu J, Kao C, Labriola MK, Gupta RT, Marin D, Wu Y, Gupta S, Zhang T, Harrison MR, George DJ, Alva A, Antonarakis ES, Armstrong AJ.
Brown LC, et al. Among authors: sedhom r.
J Immunother Cancer. 2021 Mar;9(3):e001792. doi: 10.1136/jitc-2020-001792.
J Immunother Cancer. 2021.
PMID: 33653800
Free PMC article.